Introduction
A recent review of the literature has revealed no published report of overdosage with pizotifen. We wish to report a case which recently presented to the accident and emergency department.
Case report
A 16 year old girl with a three year history of migraine and one year history of depression had been taking pizotifen 1 mg three times daily for 2 months without adverse effects. On the day of admission she had taken 60 x 0.5 mg tablets ofpizotifen (Sanomigran, Sandoz) four hours previously, but no other tablets. She was complaining of blurred vision and colicky abdominal pain. On examination she was drowsy, flushed, pyrexial at 38°C, with dilated pupils, a sinus tachycardia of 120 beats/minute and blood pressure of 110/ 60 mm Hg. Gastric lavage failed to reveal any tablets. Twelve hours after admission she complained of feeling uncomfortably hot. Her skin was dry and her temperature had risen to 39°C. Clinical examination revealed a sinus tachycardia but was otherwise unhelpful and investigations failed to reveal any cause for the pyrexia. Both the pyrexia and tachycardia persisted for approximately 10 hours before settling spontaneously ( Figure 1 ).
Discussion
Pizotifen is a benzocycloheptathiophene which is structurally related to the tricyclic antidepressant drugs. It A recent review of the role of serotonin in hypothalamic temperature regulation concluded that an increase of serotoninergic activity resulted in an elevation of body temperature3 in which case hypothermia might be expected to follow an overdose of a serotonin inhibitor. It would seem more likely that the anticholinergic properties of pizotifen were responsible for the clinical manifestations of this overdose.
Intravenous physostigmine has been advocated for the treatment of overdosage with drugs possessing anticholinergic properties, principally for reversing central side effects such as delirium and coma. However, its short duration of action necessitates frequent administration (every 45 minutes or less) and carries the risk, common to all analeptics, of precipitating convulsions.4 Since we are not able to state the relative contributions of central and peripheral mechanisms to the production of pyrexia in pizotifen overdosage, we cannot predict what benefits might accrue from the use of physostigmine, or from the use of other anticholinesterase drugs which are not so effective in their penetration of the blood-brain barrier. Phenothiazines must not be used to reduce the temperature as they possess potent anti-muscarinic activity which will exacerbate the symptoms of overdosage.' In the case reported above, symptomatic treatment with tepid sponging and a cooling fan appeared to be sufficient.
